Keyword Analysis & Research: keynote 189

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
keynote 1891.590.935829411
keynote1.920.6838777
1890.40.1793223

Keyword Research: People who searched keynote 189 also searched

Keyword CPC PCC Volume Score
keynote 1890.810.8783049

Search Results related to keynote 189 on Search Engine

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/32150489/

    WebMay 10, 2020 · Purpose: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 …

    DA: 73 PA: 20 MOZ Rank: 18

  • Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/36809080/

    WebFeb 23, 2023 · Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10;41 (11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21. Authors.

    DA: 22 PA: 91 MOZ Rank: 15

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell …

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1801005

    WebApr 16, 2018 · (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680 .) Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell lung...

    DA: 40 PA: 3 MOZ Rank: 16

  • Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell ... - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/29658856/

    WebMay 31, 2018 · Conclusions: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.

    DA: 86 PA: 22 MOZ Rank: 20

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small …

    nejm.org

    https://www.nejm.org/doi/pdf/10.1056/NEJMoa1801005

    WebApr 16, 2018 · (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680.) Inhibitors. of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell lung...

    DA: 81 PA: 49 MOZ Rank: 29

  • First-Line Selpercatinib or Chemotherapy and Pembrolizumab in

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa2309457

    WebOct 21, 2023 · On the basis of the results of the KEYNOTE-189 trial, pembrolizumab with a platinum-based drug and pemetrexed has become one of the standard treatments for patients with untreated advanced or...

    DA: 13 PA: 24 MOZ Rank: 49

  • 973MO KEYNOTE-189 5-year update: First-line pembrolizumab …

    annalsofoncology.org

    https://www.annalsofoncology.org/article/S0923-7534(22)02952-0/fulltext

    Web973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC - Annals of Oncology. Abstract | Volume 33, SUPPLEMENT 7, S992-S993, September 2022.

    DA: 50 PA: 92 MOZ Rank: 66

  • FDA grants regular approval for pembrolizumab in combination …

    fda.gov

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic

    WebThe most common adverse reactions reported in ≥20% of patients in KEYNOTE-189 were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, and...

    DA: 51 PA: 39 MOZ Rank: 27

  • Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous …

    ascopubs.org

    https://ascopubs.org/doi/abs/10.1200/JCO.22.01989

    WebFeb 21, 2023 · Open access. CLINICAL TRIAL UPDATES. February 21, 2023. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. Authors: Marina C. Garassino, MD.

    DA: 60 PA: 4 MOZ Rank: 63

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or …

    ascopubs.org

    https://ascopubs.org/doi/10.1200/JCO.19.03136

    WebMar 9, 2020 · In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) …

    DA: 40 PA: 56 MOZ Rank: 28